First, these things have to be done in double-blind trials, and so the batch size here is not uncommon or unrealistic. The biopharmaceutical industry is global as well, so no surprise. It may quite as easily been in the US or UK.
The vast majority of the metabolic pathways of the commonly used animals used in the testing or development of pharmecuticals are compatible in terms of their dynamics, and in responses to hormonal and chemical stimulants, the differences are in responsiveness.
That they are tested in these animals first is viable and justified, in my opinion as someone with experience in the area. It may lead in a vast minority of cases to drugs which would have been beneficial to humans being disregarded, or in this case the opposite. But without this the case in the news wouldn't be an exception, and the number of beneficial drugs on the market would be a fraction.
I suggest the next batch of human guinea pigs are the bleeding heart liberal demonstrators camped outside Huntingdon Sciences or the Oxford Uni Research labs.
S